The first nasal administration up to 2/3 of the main endpoint CGRP receptor antagonists can quickly relieve migraines

Migraines are the most common cause of severe headaches in the worldPeople who experience frequent migraines may lose more than half of their normal lives as a result of migrainesThe disease robs patients of time with their families and affects productivityMigraines are the sixth leading cause of disability-related loss of healthy life expectancy in the world, according to the World Health Organization (WHO)According to the Chinese Association of Pain Sciences, the incidence of migraines in China is 9.3%, and more than 10% of the world's population has reported migrainesVazegepant is a third-generation high affinity, selective CGRP receptor antagonists based on Biohaven's NOJECTION platformCGRP is a neurotransmitter that dilates blood vesselsCGRP and its receptors are expressed in the nervous system regions associated with migraine pathophysiologyInhibiting the CGRP signaling pathway is a new mechanism for acute treatment of migraineBHV3500-201 is a randomized, placebo-controlled group of key 2/3 clinical studies involving 1,673 patients with acute migrainesThe study data showed a statistically significant advantage over the 10 mg and 20 mg treatment groups in the 10 mg and 20 mg treatment groups, which achieved severe symptoms associated with headache relief and no migraines within 2 hoursAmong them, the proportion of patients who achieved headache relief was 22.5% and 23.1%, respectively, compared with 15.5% in the control groupIn addition, vazegepant also performed well at multiple secondary endpoints that showed early activity, including enabling patients to quickly relieve pain within 15 minutes, return to normal function within 30 minutes, and continue to function within 48 hoursOther results from the trial are expected to be released at a medical conference in 2020the proportion of patients who reached the end of the main study in the BHV3500-201 trial (Photo: Source: Supplied)"Biohaven has now completed clinical trials of two CGRP receptor antagonists, demonstrating the value of our migraine development platform and the ability to develop products that meet patient needs," said DrVlad Coric, CEO of Biohaven Biohaven is very grateful to the patients and researchers who have contributed to the clinical development of vazegepant and rimegepant References: s S Bio Achievehavens Positive Topline Results in Pivotal Phase 2/Study of Vazegepant, The First and Last and IntraIntrain Erin CGRP Receptor Antagonist in Clinical Development for The Acute Pain of The Migraine, From https:// original title: Express, Rapid Lying, First Nasal Treatment